癌症患者更容易受到 COVID-19 侵袭性病程的影响。开发生物标志物来识别具有 COVID-19 相关死亡高风险的癌症患者，可以帮助确定谁需要早期临床干预。与侵袭性 COVID-19 风险相关的基因组区域中的 miRNA 可以代表临床结果的潜在生物标志物。血浆样本是在德克萨斯大学 MD 安德森癌症中心从受 COVID-19 影响的癌症患者 (N = 128) 中采集的。血清样本采集自罗马尼亚蒂米什瓦拉市临床急救教学医院已接种疫苗的健康个体（n = 23）。使用计算机定位克隆方法来识别与 COVID-19 风险相关的基因组区域中是否存在 miRNA：CORSAIR（COvid-19 风险相关基因组区域）。通过 RT-qPCR 测量 miRNA 水平。我们发现 CORSAIR 中 miRNA 富集。 hsa-miR-150-5p 和 hsa-miR-93-5p 血浆水平低与 COVID-19 相关死亡较高相关。 hsa-miR-92b-3p 的水平与 SARS-CoV-2 测试阳性相关。体外 TLR7/8 和 T 细胞受体 (TCR) 介导后，外周血单核细胞 (PBMC) 增加 hsa-miR-150-5p、hsa-miR-93-5p 和 hsa-miR-92b-3p 的分泌激活。在接种第二剂辉瑞 BioNTech COVID-19 疫苗后 1 至 9 个月内，健康个体的血清样本中检测到这三种 miRNA 水平升高。人类气道上皮细胞的 SARS-CoV-2 感染影响其分泌的细胞外囊泡内的 miRNA 水平。CORSAIR 中富集了 miRNA。血浆 miRNA 水平可以作为预测癌症患者与 COVID-19 相关的死亡的潜在血液生物标志物。© 2024。作者。

Cancer patients are more susceptible to an aggressive course of COVID-19. Developing biomarkers identifying cancer patients at high risk of COVID-19-related death could help determine who needs early clinical intervention. The miRNAs hosted in the genomic regions associated with the risk of aggressive COVID-19 could represent potential biomarkers for clinical outcomes.Plasma samples were collected at The University of Texas MD Anderson Cancer Center from cancer patients (N = 128) affected by COVID-19. Serum samples were collected from vaccinated healthy individuals (n = 23) at the Municipal Clinical Emergency Teaching Hospital in Timisoara, Romania. An in silico positional cloning approach was used to identify the presence of miRNAs at COVID-19 risk-associated genomic regions: CORSAIRs (COvid-19 RiSk AssocIated genomic Regions). The miRNA levels were measured by RT-qPCR.We found that miRNAs were enriched in CORSAIR. Low plasma levels of hsa-miR-150-5p and hsa-miR-93-5p were associated with higher COVID-19-related death. The levels of hsa-miR-92b-3p were associated with SARS-CoV-2 test positivity. Peripheral blood mononuclear cells (PBMC) increased secretion of hsa-miR-150-5p, hsa-miR-93-5p, and hsa-miR-92b-3p after in vitro TLR7/8- and T cell receptor (TCR)-mediated activation. Increased levels of these three miRNAs were measured in the serum samples of healthy individuals between one and nine months after the second dose of the Pfizer-BioNTech COVID-19 vaccine. SARS-CoV-2 infection of human airway epithelial cells influenced the miRNA levels inside their secreted extracellular vesicles.MiRNAs are enriched at CORSAIR. Plasma miRNA levels can represent a potential blood biomarker for predicting COVID-19-related death in cancer patients.© 2024. The Author(s).